Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08
about
The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymeraseGlycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expressionSystematic review of influenza resistance to the neuraminidase inhibitorsInfluenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistancePandemic potential of a strain of influenza A (H1N1): early findingsAssays for monitoring susceptibility of influenza viruses to neuraminidase inhibitorsSafety and efficacy of peramivir for influenza treatmentHedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapyCloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be establishedH1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural AnalysisBinding of a natural anthocyanin inhibitor to influenza neuraminidase by mass spectrometryOseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferretsCan we "hedge" against the development of antiviral resistance among pandemic influenza viruses?Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virusEstimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza virusesSelection for resistance to oseltamivir in seasonal and pandemic H1N1 influenza and widespread co-circulation of the lineagesDrug resistance in influenza A virus: the epidemiology and management.Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic.In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.Continuing challenges in influenza.Strain-specific antiviral activity of iminosugars against human influenza A virusesAntiviral drug profile of human influenza A & B viruses circulating in India: 2004-2011.Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08.Zanamivir-resistant influenza viruses with a novel neuraminidase mutationLarge-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance.Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China.Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models.Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo ExperimentsCharacterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A virusesDose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model.The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo.Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico.A severely immunocompromised child with uncomplicated oseltamivir-resistant 2009 H1N1 pandemic influenza infection.Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferretsNeuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.Oseltamivir overuse at a Chicago hospital during the 2009 influenza pandemic and the poor predictive value of influenza-like illness criteria.Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus A(H1N1), A(H1N1)2009, and A(H3N2) subtypes by melting point analysis.
P2860
Q21089768-1E91729E-51BE-4C37-BEEB-D30474BC841BQ21135459-47A54FAF-E378-45E6-896B-527E2C576779Q21261835-15743DD5-8486-4DE9-B6B7-212721FD25A5Q21562135-C4D6A5E3-810F-4560-B6E9-FAF721D93802Q24286924-22C47794-B5FB-4DDC-BD3B-FB14BF1CBB21Q27013442-12EF75D4-C156-4C04-83F0-D9840E8233C6Q27027408-09929308-A23E-493B-BCF5-361F0F5DC67BQ27307203-B19DB85E-791A-44AE-AC86-DCE9E38A69C6Q27336337-981CC8AC-CF95-45D1-BF14-7645D77F54E8Q27673887-88989346-2082-40D3-A2B8-9233C2676478Q28292279-9B5C4154-741B-4061-9A90-82CF6B0759BFQ28474889-312FE403-4FB6-4CFA-A552-8770BCF5D782Q28475628-6B83588F-C0D3-4160-B355-06AED17BF001Q28478637-D0EA4533-B4ED-4952-B50E-4EAB2F196AE6Q28541953-683E584F-FB96-4D3A-898F-BE1E6A18E5E2Q30227284-E2A0B672-75C1-44D8-AE60-A6EE6E58E7C4Q30234600-2712E56F-14FC-4CEB-BE33-839900929418Q30352557-AA9D192E-6E8C-479E-9E7B-34389B5D76D2Q30356466-85B7A4E5-610F-42B5-8F8B-264720A20B4EQ30363190-D30AD713-7924-4EC4-A860-02C41EA45C26Q30366818-19E19AD6-AB3D-4BC6-9F76-BEB5373EB3C8Q30367631-919BD7F0-A875-47D5-8DFD-5317481A55C4Q30377007-F5AE6705-BA5A-4964-B929-2E3F6F7464A0Q30379353-F9FEF144-F89C-4A90-A640-84B8B4A416E1Q30379476-977CB81B-FEFB-4794-9453-87BA9B0349A4Q30383194-B72D775B-3250-45D0-AA9A-1187D4BC4120Q30386485-21CFA005-A059-4CEA-BFD9-EB8CCC4C5B4EQ30391856-3C42E296-72C7-4C4D-8989-D8A4568CC580Q30392964-5C107256-2BAF-4930-8F32-BA75BD8B164BQ30393969-FF1D5AC9-594B-4131-9222-94D0FB12F880Q30394067-453C9E88-8431-4D5F-B603-72DB9050E2BFQ30394366-D26FFE48-ED01-4CFE-9D08-6ACEC96F8F01Q30396361-59F36035-28B1-485E-815B-3A051BD87037Q30399321-00A93677-7E2F-474C-AFE2-63B7D77ADA60Q30401070-C9B9583D-A4A5-4DF0-917D-951929CFAFE1Q30407925-FC82A316-3D20-488A-9511-2E795870BCF8Q30408105-DEDEF3BD-5A1E-4DD6-B660-4A0CA5B4D90FQ30408617-EF62BA70-9BC4-47D7-8A26-3CF7D9195F57Q30409023-165C8A01-2F91-4FB1-88E6-61982966320CQ30409553-89900220-AC63-40DA-8032-A11F367F27F1
P2860
Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08
@ast
Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08
@en
type
label
Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08
@ast
Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08
@en
prefLabel
Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08
@ast
Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08
@en
P2093
P2860
P356
P1476
Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08
@en
P2093
Angie Lackenby
Katrine Borgen
Olav Hungnes
Siri H Hauge
P2860
P304
P356
10.3201/EID1502.081031
P577
2009-02-01T00:00:00Z